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Abstract
Most mammalian genes are able to express several splice variants in a phenomenon known as alternative splicing. Serious
alterations of alternative splicing occur in cancer tissues, leading to expression of multiple aberrant splice forms. Most
studies of alternative splicing defects have focused on the identification of cancer-specific splice variants as potential
therapeutic targets. Here, we examine instead the bulk of non-specific transcript isoforms and analyze their level of disorder
using a measure of uncertainty called Shannon’s entropy. We compare isoform expression entropy in normal and cancer
tissues from the same anatomical site for different classes of transcript variations: alternative splicing, polyadenylation, and
transcription initiation. Whereas alternative initiation and polyadenylation show no significant gain or loss of entropy
between normal and cancer tissues, alternative splicing shows highly significant entropy gains for 13 of the 27 cancers
studied. This entropy gain is characterized by a flattening in the expression profile of normal isoforms and is correlated to
the level of estimated cellular proliferation in the cancer tissue. Interestingly, the genes that present the highest entropy
gain are enriched in splicing factors. We provide here the first quantitative estimate of splicing disruption in cancer. The
expression of normal splice variants is widely and significantly disrupted in at least half of the cancers studied. We postulate
that such splicing disorders may develop in part from splicing alteration in key splice factors, which in turn significantly
impact multiple target genes.
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Introduction
The majority of mammalian genes produce alternative
transcripts as part of their normal expression program [1–4].
Alternative transcripts include splicing, polyadenylation and
transcription initiation variants which can be expressed differen-
tially in different tissues [4–7] providing the fine tuning of gene
expression required for cell differentiation and tissue-specific
functions. Disruptions in the balance of alternative transcripts,
especially at the splicing level, are known to affect angiogenesis [8],
cell differentiation [9] and invasion [10]. A large body of evidence
has established connections between alternative splicing defects
and cancer, so that the identification of transcript isoforms is now
considered an important avenue in cancer diagnosis and therapy
[11,12].
The disruption of splicing isoform expression in cancer may
result from very different underlying genetic events. On one hand,
mutations in cis-regulatory sequences lead to the abnormal
expression of specific isoforms, as observed for example in the
BRCA1 gene in breast and ovarian cancer [13]. Another class of
event includes alterations of the mRNA processing machinery or
its signalling pathway. These may affect the splicing of specific
genes such as CD44 [14–16], but may also cause wider
perturbations of isoform expression as the processing of multiple
genes can be simultaneously affected [17–20]. Evidence for wider
changes in alternative transcription linked with cancer are present
for instance in EST databases, where a large fraction of splice
variant are actually tumor-specific [21]. However, while most
studies of splicing and cancer attempt to isolate ‘‘signature’’ splice
variants with significant over-expression in disease cells, no
published work to date has focused on the bulk of splicing
disruption that potentially arises when the splicing machinery is
impaired.
The aim of the present study is to evaluate the extent and
modalities of non-specific alternative transcript disruptions in
cancer. Instead of seeking ‘‘interesting’’ signature isoforms, we
analyzed the distribution of all isoforms from a single gene in a
given tissue. We postulated that, in a tissue where the splicing
machinery is impaired, the distribution of isoforms may be more
disordered than in a control tissue. To measure the level of
disorder in cDNA and cDNA tag libraries, we borrowed the
notion of entropy from information theory. We applied this
measure to all three types of alternative transcription, comparing
isoform distributions in pairs of disease and normal tissues. Our
results show that neither alternative polyadenylation nor alterna-
tive transcription initiation are associated with a disordered
isoform expression. However, in half of the cancers studied,
alternative splicing showed a highly significant entropy gain
relative to the corresponding normal tissues. We analyze this
entropy gain and discuss its possible causes.
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Results
Isoform Entropy: Definition
Given a random variable X with probabilities P(xi) for discrete
set of events x1,….,k, Shannon’s entropy, also known as
Information Entropy, is defined by:
H Xð Þ~{SP xið Þlog P xið Þ
The entropy, and thus the disorder, is maximal when the
probability of all the events P(xi) are equal and thus the outcome
is most uncertain. Here, Shannon’s entropy is applied to the
expression profiles of different transcript isoforms for a given
context. In the Figure 1 example, Gene1 has 4 alternative splice
forms (SP1…SP4) and we are interested in their expression in
normal cerebellum and cerebellum tumor tissues. For each splice
form, we count the number of transcripts observed in different
tissue types (for instance ESTs/cDNAs matching splice form SP1
are observed 4 times in cerebellum tumor libraries and once in
normal tissue libraries). For this gene, isoform entropy across the
four splice forms is higher in tumor than in normal cerebellum
tissues, reflecting a more uniform tissue distribution of isoforms in
the tumor libraries.
Cancer Tissues Have Higher Splicing Isoform Entropy
We hypothesised that impairment of the transcriptional or post-
transcriptional control machinery in cancer or other diseases
should result in the loss of a tissue-specific expression pattern of
certain transcript isoforms. This loss can be measured by a gain of
entropy in the expression pattern of isoforms of a given gene. By
averaging entropy gains or losses on a sufficient number of genes
Author Summary
RNA splicing is the process by which gene products are
pieced together to form a mature messenger RNA (mRNA).
In normal cells, RNA splicing is a tightly controlled process
that leads to production of a well-defined set of mRNAs.
Cancer cells, however, often produce aberrant, mis-spliced
mRNAs. Such disorders have not been quantified to date.
To this end, we use a well-known measure of disorder
called Shannon’s entropy. We show that overall splicing
disorders are highly significant in many cancers, and that
the extent of disorder may be correlated to the level of cell
proliferation in each tumor. Surprisingly, genes that
control the splicing mechanism are unusually frequent
among genes affected by splicing disorders. This suggests
that cancer cells may withstand harmful chain reactions in
which splicing defects in key regulatory genes would in
turn cause extensive splicing damage. As mis-spliced
mRNAs are widely studied for cancer diagnosis, awareness
of these global disorders is important to distinguish
reliable cancer markers from background noise.
Figure 1. Example of Shannon’s entropy calculation for a gene with four splicing isoforms SP1..SP4. EST counts are provided for each
isoform in a normal and cancer tissue. In this example, isoform entropy is higher in the cancer tissue (1.38 versus 1.16 bits).
doi:10.1371/journal.pcbi.1000011.g001
Transcript Entropy and Splicing Disorder
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expressed in a disease/normal tissue pair, we should observe a
significant entropy bias if isoform expression is altered in this
disease.
We obtained transcript isoform collections from the FAN-
TOM3 database [1] for initiation variants and the ATD database
[22] for polyadenylation and splicing variants. We then related
isoforms to cDNA or cDNA tag counts and mapped each cDNA
or tag to its tissue/disease information using the EvoC ontology
[23] for ESTs/cDNAs or direct parsing of CAGE/SAGE
databases as explained in Materials and Methods. A gene was
considered in the entropy calculation only if it had at least two
alternative isoforms supported by at least 10 different transcripts
from three separate libraries, thus a total of at least 20 transcripts
mapped to each gene considered. In order to measure isoform
entropy changes in a disease/normal tissue pair, we required that
at least 50 genes and 100 isoforms were found expressed in both
the normal and disease tissues. By considering only isoforms that
were observed in both states, we excluded from our analysis
spurious isoforms that are prevalent in many cancer EST libraries
[24].
We define the entropy ratio of a gene as the ratio of the entropy
of this gene in the disease to the entropy of the same gene in the
normal tissue. The entropy ratio of a disease/normal tissue pair is
the average of the entropy ratios of all genes available in this tissue
pair. Figure 2 presents entropy ratios for different diseases with
respect to alternative initiation (A), polyadenylation (B) and
splicing (C). An entropy ratio of one means that isoform entropy
does not vary between disease and normal tissue (thick line in
Figure 2). To estimate significance boundaries, random assays
were performed by dividing the average entropy of 1000 randomly
picked genes from any disease/tissue state by that of another
randomly picked set of 1000 genes from any other disease/tissue
state and repeating this process 10,000 times. This process was
performed independently on the three isoform datasets. Values for
the highest and lowest percentile are represented by red and green
vertical lines, respectively.
Entropy ratios for alternative initiation and polyadenylation did
not ever exceed the significance boundaries (Figure 2A and 2B) in
the 6+8 cancer/normal tissue pair studied. This suggests that
expression of alternative polyadenylation and initiation isoforms
does not present large scale alterations in cancer. Alternative
splicing however was quite different with 24 of the 27 cancer
tissues studied showing a higher level of entropy than their normal
counterpart (Figure 2C and Table S1). This entropy gain was
highly significant in 13 cases, suggesting that the expression of
splicing isoforms is strongly disrupted in certain cancers. In
none of the 27 cases studied did the normal tissues show
significantly higher entropy than disease tissues, and none of the
Figure 2. Ratio of average isoform entropy in cancer versus normal tissues. A value of 1 indicates that average entropy per gene in cancer
tissue = average entropy per gene in normal tissue. The first number in parentheses corresponds to the number of genes that were used to calculate
entropy gains, and the second corresponds the total coverage in ESTs/cDNAs/SAGEs for the diseased and normal tissue types. Only tissue types for
which at least 50 genes and 100 isoforms were available to measure the entropy ratio are shown. (A) alternative initiation. (B) Alternative
polyadenylation. (C) Alternative splicing.
doi:10.1371/journal.pcbi.1000011.g002
Transcript Entropy and Splicing Disorder
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three non-cancer diseases (arthritis, ascites and schizophrenia)
presented a significant entropy change between normal and
disease tissues.
The observed entropy bias is not imputable to sampling
differences in normal and cancer libraries. The number of
ESTs/cDNAs used to calculate entropy did not differ significantly
between normal or disease tissues (Table S1), mainly due to the
fact that we considered only isoforms that are expressed both in
disease and normal tissues. Furthermore, Pearson’s correlation
tests (Table S1) showed no relationship between the entropy ratio
and differences in the numbers of ESTs/cDNAs between normal
and disease tissues (P = 0.28) or between the entropy ratio and the
total size of libraries (P = 0.12). The observed gain in entropy can
therefore not be attributed to a size effect of cancer EST libraries.
Splice Factors Are Over-Represented Among Splice-
Impaired Genes
In the ten most disrupted cancer tissues, splicing entropy gains
were caused by 16 to 258 significantly disrupted genes, or 30%–
68% of the gene set available for entropy calculation in these
tissues. This suggests that splicing perturbation is caused by factors
that regulate multiple genes at the same time. Sets of splice-
disrupted genes from different tissues show little overlap therefore
we cannot isolate a list of genes displaying a generally higher rate
of splicing disruption. However, a clear functional trend appears
when high entropy gain tissues are pooled together. In the ten
cancer tissues that displayed the highest gain in splicing entropy
(from stomach/carcinoma to brain/astrocytoma, Figure 2), we
analyzed all genes showing a splicing entropy gain (414 genes) for
functional enrichment. Interestingly, the most over-represented
terms among splice-disrupted genes either contain ‘‘RNA splicing’’
or are higher level terms that incorporate RNA splicing (Table 1).
The ‘‘RNA splicing’’ class mostly comprises splice factors. This
suggests that splicing alterations in a few key splice factors could be
involved in the more extensive splicing disruption observed in the
high entropy-gain tissues. This enrichment is observable only after
cancer tissues are pooled, which means the number of disrupted
splice factors in a single disease is low. A total of 13 splice factors
show a significant increase in splicing entropy in the cancer tissues
studied (Table S2). Most are constitutive splice factors, only three
(TRA2B, U2AF1, SF3A2) being involved in alternative splicing
regulation.
Splice factors are subject to alternative splicing at higher rates
than average genes: 72% of the 58 annotated splice factors in
Gene Ontology [22] have at least one alternative splice form in the
ATD database [25], with an average of 5.4 isoform per gene,
compared to 62% alternative splicing and 3.4 isoform per gene in
the total ATD gene set. To test whether this bias could explain the
over-representation of splice factors among disrupted genes in the
high entropy gain cancers, we performed the same GO-term
analysis among splice-disrupted genes in the ten disease categories
displaying the lowest entropy gain. We could not observe any
functional bias in this gene set (not shown). Therefore, splicing
deregulation of splice factors is a hallmark of tissues where overall
splicing is deregulated. This again designates misplicing of splice
factors as a possible cause of wider splicing disruption in these
tissues.
Splicing Entropy Gain Is Correlated to Proliferation
Signature
Although tumors are diverse and heterogeneous, they all share
the key ability to proliferate at a higher level than normal tissue
and this despite the very tight control that the organism usually
exerts on cell proliferation. To test potential links between
disordered isoform expression and higher levels of proliferation,
we classified the cancer types that deregulate the splicing
mechanism (Figure 2C) in function of their proliferative potential.
To evaluate proliferation, we extracted the 188 genes from the
‘‘cell cycle’’ module of Stuart et al. [26], a cluster of coexpressed
genes shown to be enriched in elements that are overexpressed in
highly proliferative cells and whose high expression is a marker of
entry into the cell cycle [27]. We manually verified each of these
188 genes (Table S3) and confirmed that 92 were shown to be
specifically over-expressed during one of the replicative phases of
the cell cycle and another 17 bore significant proof of being over-
expressed in proliferating cells. We thus used a high expression of
these markers as a surrogate for a high level of proliferation. In
order to obtain a ‘‘proliferation index’’ of cancer samples, we
computed the median expression level of the 188 markers in each
of 3787 published Affymetrix microarray experiments performed
on cancer samples [28]. Samples were then binned into five
categories from low to high proliferation, as shown in Figure 3. To
relate proliferation levels to splicing entropy results, we considered
only microarray samples that contained the exact same keywords
as disease tissues in Figure 2C. Results are shown in Figure 4. Cell
proliferation, as measured from the expression of cell cycle genes,
is significantly correlated to splicing entropy gains.
This observation led us to question the possible correlation
between splicing entropy and cellular proliferation in a non-
pathological context. We compared the splice isoform entropy of
foetal and adult tissues in the same manner we compared disease
and normal tissues (Figure 5). While foetal tissues are expected to
present higher levels of proliferation than their adult counterparts,
we could not observe any significant entropy gain in foetal tissues.
This suggests the higher isoform entropy observed in highly
proliferating cancers is only indirectly related to proliferation
(proliferation indices of foetal tissues could not be obtained due to
insufficient foetal microarray data).
Discussion
While previous studies of cancer-related splicing alterations
have focused mainly on the discovery of ‘‘aberrant’’ splice variants,
we looked instead at changes in the balance of variants expressed
in both healthy and cancer tissues. This new perspective enabled
us to characterize another kind of splicing disorder in which splice
Table 1. Gene Ontology term biases for genes with entropy
gain in high-entropy cancer tissues, as measured using the
Gene Ontology Toolbox [38].
Enriched GO Term P-value
Cellular physiological process 1.55E-10
RNA metabolism 2.87E-10
RNA processing 3.48E-08
mRNA metabolism 4.74E-08
RNA splicing, via transesterification reactions 8.89E-08
RNA splicing with bulged adenosine as nucleophile 8.89E-08
Nuclear mRNA splicing, via spliceosome 8.89E-08
Primary metabolism 1.35E-07
RNA splicing 1.69E-07
Enrichment is measured relatively to all genes in the genome.
doi:10.1371/journal.pcbi.1000011.t001
Transcript Entropy and Splicing Disorder
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variant expression profiles are significantly flattened in tumors.
While isoforms from the same gene are usually differentially
expressed in a given tissue, with clear minor and major forms,
these expression differences are reduced in cancer and this leads to
a raise of isoform entropy. Although controlled over/under-
expression events may in principle produce a flattened profile, we
find unlikely that the generalized entropy gain observed in cancer
could result from a combination of multiple controlled changes in
isoform expression. The entropy gain is more likely a sign of a
general loss of regulation involving widespread, non-specific
perturbations of alternative splicing. We did not observe such
cancer-related disorders in alternative transcription initiation and
alternative polyadenylation, the two other processes associated
with expression of disease-specific isoforms.
Previous efforts to identify cancer-specific splice forms, either
through EST analysis or experimental means, have mostly ignored
non-specific, large-scale disruptions. An exception is the study by
Xu and Lee [29] which sought splice forms with statistically
significant expression changes between normal and tumor EST
libraries. In that sense, these authors were looking for events that
would cause an entropy reduction, not an entropy gain. However,
they also discussed the impact of unspecific disruptions and
analyzed expression patterns that may lead to cancer-specific
isoforms (Figure 6). The most frequent patterns leading to cancer-
specific events were the loss of a normal isoform S, and the switch
in expression between normal (S) and cancer-specific (S’) isoforms.
A general entropy gain would go against the occurrence of such
events, which makes these patterns even more interesting on a
background of entropy gain. Contrarily, the ‘‘gain of S’’’ category
is directly correlated to a rise of entropy (i.e. the ‘‘tumor’’ situation
has higher entropy). Therefore, in a context of general entropy
gain, events of the ‘‘gain of S’’’ category, even when statistically
significant, could merely reflect the wider splicing disruption and
should be considered with caution. Xu and Lee rightly noted that
this category, which produces only a small fraction of cancer-
specific splice forms, may be related to a loss of splicing specificity
in tumors.
There is now ample evidence that changes in splice factor
expression, due for instance to kinase activation [14], disrupt
splicing patterns in tumors [16,18–20,30,31]. Figure 7, box A
presents the most common of these effects, where an up-regulated
splice factor causes expression of a rare or aberrant splice form.
Splice factors previously analyzed for such dysfunctions include
SF2/ASF, U2AF-65, SFRS2, SFRS3, SRm160, hnRNP A1/A2,
Figure 3. Meta-analysis method to obtain proliferative indices of cancer samples in microarray experiments. The 188 genes of the ‘‘cell
cycle’’ cluster in the conserved coexpression network identified by Stuart et al. [26] were extracted. Each of the 3787 cancer-related samples was
classified in one of 5 separate bins of same size in function of the average expression level of these 188 genes. The high proliferation signature bin
(High PS) corresponds to the 20% of samples that have the highest mean expression level of the 188 genes; the lowest proliferation signature bin
(Low PS) corresponds to the 20% of samples that have the lowest mean expression level of the 188 genes.
doi:10.1371/journal.pcbi.1000011.g003
Transcript Entropy and Splicing Disorder
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Figure 4. Correlation between the proliferation signature of different cancers and their splicing entropy ratio.
doi:10.1371/journal.pcbi.1000011.g004
Figure 5. Ratio of average isoform entropy in fetus versus adult tissues for alternative splicing. The first number in parentheses
corresponds to the number of genes that were used to calculate entropy gains, and the second corresponds to the total coverage in ESTs/cDNAs for
the fetal and adult tissue types.
doi:10.1371/journal.pcbi.1000011.g005
Transcript Entropy and Splicing Disorder
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and TRA2-b, all acting both in alternative and constitutive
splicing. Although these factors may potentially target many genes,
studies have focused on specific targets such as CD44 and have not
examined more widespread splice defects. The splicing disruptions
that we observed apparently affect a larger number of transcripts
and are characterized by a loss of splice form regulation. Although
this phenomenon might occur as a byproduct of the above
mechanism, its association with the mis-splicing of splice factors,
prevalently of the constitutive type, leads us to postulate a second
process (Figure 7, box B) in which mis-splicing of general splice
factors would cascade into a wider splicing disruption and entropy
gains. Among the 13 splice factors that displayed splicing
disruptions in our study, two were already known to regulate
their own splicing: SFRS3 and TRA2-b [15,28]. In each case,
overexpression of the splice factor activated the inclusion of stop
codon-containing exons [15,28] producing transcripts subject to
nonsense-mediated decay [32,33]. Both genes have additional
isoforms that are not NMD-prone (Figure S1) and may contribute
to the mis-splicing of other genes.
A possible link between the two pathways in Figure 7 naturally
comes to mind when considering that a change in splice factor
expression in pathway ‘‘A’’ could alter the splice variant balance of
other splice factors in pathway ‘‘B’’. This transition may occur
preferentially in highly proliferating tumors, where we observed
the strongest splicing disruption. Splicing perturbation is know-
ingly correlated to proliferation [31] however no causal relation-
ship between these events has been identified yet. Perhaps the
splicing mechanism has trouble in trying to keep up with the
accelerated pace of cell proliferation or a general disorder in
splicing is causing failure in the regulation of cell cycle.
Independently of any mechanistic hypothesis, splicing entropy
measures show that widespread splicing disruption may be
prevalent in most cancer tissues. In such a context of high splicing
entropy, therapeutic avenues involving the reprogrammation of
mis-spliced isoforms [34] would have a limited interest. As already
recognized in different studies [35,36] splice factors or their
regulatory machinery may turn out as better therapeutic targets.
Materials and Methods
Alternative Transcript and Expression Data
Transcripts and expression data for each type of transcriptional
variation (initiation, splicing, polyadenylation) were obtained from
the following sources.
Alternative initiation isoforms were obtained from the CAGE
Basic/Analysis databases at http://fantom31p.gsc.riken.jp/ca-
ge_analysis/hg17/. This database classifies 3,106,472 CAGE tags
into 450,228 transcription clusters (TC) further grouped into
32,351 transcription units (TU). TCs and TUs are two
operationally defined units proposed in FANTOM3 [1] used to
characterize promoters and genes respectively. We considered
only those TCs that bore proof from at least 3 different CAGE
libraries and 10 transcripts. These TCs were downloaded from the
RIKEN website as well as the mappings of CAGE transcripts to
these TCs in a given tissue type. This allowed us to create a
relational database in which each TC could be queried to display
its mapped CAGEs in each tissue type and the TU to which it
belongs. For each normal/disease tissue pair we could therefore
query a list of TCs common to both tissue types, link these TCs to
their specific TUs and obtain the number of CAGEs mapped to a
each of these TCs from the normal tissue library and from the
disease tissue library.
Alternative polyadenylation isoforms were downloaded from the
EBI ATD database, Human Release 1 (31 May 2005) [25] at
http://www.ebi.ac.uk/atd/humrel1.html. Here, we only consid-
ered poly(A) sites located in the 39-most exon of the gene because
poly(A) sites located in upstream exons can belong to different
splice forms. Since alternative splicing and polyadenylation can
interfere [37], such events cannot be safely attributed to either
phenomena. Again, each alternative polyadenylation event had to
Figure 6. Classification of cancer-specific splice events as
proposed by Xu and Lee [29]. Three typical cases of cancer-specific
events are shown. Numbers are EST counts supporting each splice form.
S: putative normal splice form; S’: putative cancer-specific splice form.
Percentages in parenthesis indicate the proportion of overall cancer-
specific events that belong to each category according to [29].
doi:10.1371/journal.pcbi.1000011.g006
Figure 7. Models for mechanisms leading to specific or non-
specific expression of splice isoforms in cancer tissues. Dotted
arrows: hypothetical links. Box A: Known trans effect in which change in
splice factor activation results in specific changes in the expression
levels of several splice variants. Box B: Possible alternative mechanism in
which disruption of SR protein splicing induces a wider deregulation of
splice isoform expression. The dotted arrow between boxes indicates a
possible link between specific and non-specific splicing disruption that
may occur preferentially in proliferating tumors.
doi:10.1371/journal.pcbi.1000011.g007
Transcript Entropy and Splicing Disorder
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be supported by three different cDNA libraries and 10 transcripts,
giving a total of 206,138 transcripts mapped to 13,367 poly(A) sites
for 4400 genes. These 13,367 poly(A) sites were downloaded from
the ATD website as well as the mapping of ESTs, cDNAs and
SAGES to these isoforms. cDNA and EST transcripts were then
linked to the eVOC 2.6 ontology through their Genbank accession
identifiers and SAGE transcripts were manually parsed for simple
tissue descriptors that were identical to eVOC 2.6 ontology terms
(39 descriptors from the Gene Expression Omnibus [27]). This
allowed us to create a relational database in which each poly(A)
isoform could be queried to display its mapped transcripts in each
tissue type and the Ensembl gene ID to which it belonged. For
each normal/disease tissue pair we could therefore query a list of
poly(A) isoforms common to both tissue types, link these isoforms
to their specific Ensembl gene identifier and obtain the number of
transcripts mapped to a each of these isoforms from the normal
tissue library and from the disease tissue library.
Alternate splice isoforms were also downloaded from the EBI
ATD database, Human Release 1. Again, 3 separate libraries and
10 transcripts were required to establish a splice form. Transcripts
that mapped to multiple isoforms were excluded from the study
bringing the total number of transcripts/isoforms/genes in the
database from 808845 / 52742 / 14791 to 444799 / 47308 /
12281. These 47,308 alternative splice sites were downloaded
from the ATD website as well as the mapping of ESTs and
cDNAs to these isoforms. cDNA and EST transcripts were then
linked to the eVOC 2.6 ontology through their Genbank
accession identifiers. This allowed us to create a relational
database in which each alternative splicing isoform could be
queried to display its mapped transcripts in each tissue type and
the Ensembl gene ID to which it belonged. For each normal/
disease tissue pair we could therefore query a list of splicing
isoforms common to both tissue types, link these isoforms to their
specific Ensembl gene identifier and obtain the number of
transcripts mapped to a each of these isoforms from the normal
tissue library and from the disease tissue library.
Expression of ‘‘Cell Cycle’’ Genes and Proliferation
Categories
Cell-cycle specific genes were extracted from the conserved co-
expression network defined by Stuart et al. [26] and available for
download at http://cmgm.stanford.edu/,kimlab/multispecies. A
matrix of gene-gene Euclidean distances was computed and used
for hierarchical clustering using R software. The tree obtained was
then split into several groups by specifying a cutoff height of 10. All
genes in the ‘‘cell cycle’’ cluster were extracted and their respective
Locuslink ID used for annotation.
Microarray expression data was obtained from the Gene
Expression Omnibus [28] selecting Affymetrix GPL96 platform
(8340 different samples). We parsed microarray sample descrip-
tions for the presence of any EvoC ontology keyword inherited
from the top level term%neoplasia& and then manually checked
to see if the description genuinely corresponded to a cancer-related
experiment. From a set of 8340 microarray samples studied, 3787
samples corresponded to cancer-related microarray experiments.
Proliferation categories were then attributed to each sample based
on the median ranking (MR) of the expression level of the 188
genes from the cell cycle node, as follows: High proliferation : MR
in the top 20% of the genes on array.; Medium-high proliferation :
MR between top 20% and top 40% of genes on array; Medium
proliferation : MR between the top 40% and top 60% of the genes
on array; Medium-low proliferation: MR between bottom 20%
and bottom 40% of genes on array; Low proliferation: MR in the
bottom 20% of genes on array.
Supporting Information
Figure S1 Alternative forms of splice factors TRA2B and
SFRS3 in human, taken from the ASTD database, beta site
(http://www.ebi.ac.uk/tc-test/astd/main.html). Major and NMD
forms are indicated for each gene.
Found at: doi:10.1371/journal.pcbi.1000011.s001 (1.57 MB TIF)
Table S1 Raw data from Figure 2 and correlation tests showing
independance of entropy ratio to transcript coverage and number
of genes tested.
Found at: doi:10.1371/journal.pcbi.1000011.s002 (0.02 MB XLS)
Table S2 List of splice-disrupted splicing factors (high entropy
gain in cancer).
Found at: doi:10.1371/journal.pcbi.1000011.s003 (0.02 MB XLS)
Table S3 Detailed annotation of genes used to calculate
proliferation level.
Found at: doi:10.1371/journal.pcbi.1000011.s004 (0.14 MB
DOC)
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